These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 22428052)
1. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. Christians A; Hartmann C; Benner A; Meyer J; von Deimling A; Weller M; Wick W; Weiler M PLoS One; 2012; 7(3):e33449. PubMed ID: 22428052 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615 [TBL] [Abstract][Full Text] [Related]
3. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646 [TBL] [Abstract][Full Text] [Related]
4. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Lee JY; Park CK; Park SH; Wang KC; Cho BK; Kim SK Childs Nerv Syst; 2011 Nov; 27(11):1877-83. PubMed ID: 21789683 [TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275 [TBL] [Abstract][Full Text] [Related]
6. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811 [TBL] [Abstract][Full Text] [Related]
7. MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry. Trabelsi S; Mama N; Ladib M; Karmeni N; Haddaji Mastouri M; Chourabi M; Mokni M; Tlili K; Krifa H; Yacoubi MT; Saad A; H'mida Ben Brahim D Clin Transl Oncol; 2016 Apr; 18(4):391-7. PubMed ID: 26289551 [TBL] [Abstract][Full Text] [Related]
8. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay? Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H J Neurosurg; 2019 Mar; 130(3):780-788. PubMed ID: 29726772 [TBL] [Abstract][Full Text] [Related]
9. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme. Sunwoo L; Choi SH; Park CK; Kim JW; Yi KS; Lee WJ; Yoon TJ; Song SW; Kim JE; Kim JY; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Chang KH J Magn Reson Imaging; 2013 Feb; 37(2):351-8. PubMed ID: 23023975 [TBL] [Abstract][Full Text] [Related]
10. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Jeuken JW; Cornelissen SJ; Vriezen M; Dekkers MM; Errami A; Sijben A; Boots-Sprenger SH; Wesseling P Lab Invest; 2007 Oct; 87(10):1055-65. PubMed ID: 17700563 [TBL] [Abstract][Full Text] [Related]
11. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344 [TBL] [Abstract][Full Text] [Related]
12. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. Zhao H; Wang S; Song C; Zha Y; Li L World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166 [TBL] [Abstract][Full Text] [Related]
13. Johannessen LE; Brandal P; Myklebust TÅ; Heim S; Micci F; Panagopoulos I Cancer Genomics Proteomics; 2018; 15(6):437-446. PubMed ID: 30343277 [TBL] [Abstract][Full Text] [Related]
14. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593 [TBL] [Abstract][Full Text] [Related]
15. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398 [TBL] [Abstract][Full Text] [Related]
16. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Brandner S; McAleenan A; Kelly C; Spiga F; Cheng HY; Dawson S; Schmidt L; Faulkner CL; Wragg C; Jefferies S; Higgins JPT; Kurian KM Neuro Oncol; 2021 Sep; 23(9):1457-1469. PubMed ID: 34467991 [TBL] [Abstract][Full Text] [Related]
17. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related]
18. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
19. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115 [TBL] [Abstract][Full Text] [Related]
20. Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. Rosas-Alonso R; Colmenarejo-Fernandez J; Pernia O; Rodriguez-Antolín C; Esteban I; Ghanem I; Sanchez-Cabrero D; Losantos-Garcia I; Palacios-Zambrano S; Moreno-Bueno G; de Castro J; Martinez-Marin V; Ibanez-de-Caceres I Clin Epigenetics; 2021 Mar; 13(1):52. PubMed ID: 33750464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]